Brain-derived neurotrophic factor (BDNF) therapy refers to strategies designed to increase BDNF signaling in the central nervous system in order to support neuronal survival, synaptic plasticity, and network resilience[1][2]. Because impaired neurotrophic support is implicated across Alzheimer's disease, Parkinson's disease, Huntington's disease, and traumatic brain injury, BDNF-directed treatment remains a recurring translational goal despite difficult delivery constraints[1:1][3]. BDNF is the most abundant neurotrophin in the central nervous system and plays critical roles in neuronal development, synaptic plasticity, learning, and memory[4].
BDNF is a 119-amino acid polypeptide belonging to the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)[5]. BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, triggering downstream signaling cascades including:
BDNF is synthesized as a precursor (proBDNF) that can be cleaved to mature BDNF. ProBDNF preferentially binds to the p75NTR receptor, which can induce apoptosis in some contexts, adding complexity to therapeutic targeting[9].
BDNF levels are reduced in multiple neurodegenerative conditions:
Recombinant human BDNF (rhBDNF) has been tested in clinical trials for amyotrophic lateral sclerosis and diabetic neuropathy[14]. However, the challenge of delivering sufficient BDNF to the CNS while avoiding peripheral side effects has limited clinical development[15].
Viral vector-mediated gene therapy aims to achieve sustained BDNF expression in target brain regions:
AAV-BDNF: Adeno-associated virus (serotype 2 or 9) carrying the BDNF gene has shown promise in preclinical models of Parkinson's disease and Alzheimer's disease[16]. AAV-BDNF delivered to the basal forebrain improved memory in aged non-human primates[17].
Neurturin and AAV-NRTN: Although not BDNF, neurturin (NTN) is a TrkB ligand that has been tested in Parkinson's disease gene therapy trials (CERE-120), providing proof-of-concept for neurotrophic factor delivery[18].
Exercise: Aerobic exercise is the most robust physiological stimulus for BDNF expression, mediated through muscle-derived factors (myokines) and neuronal activity[19]. Regular exercise improves memory and slows cognitive decline in humans[20].
Pharmacologic Agents:
Dietary Approaches: Caloric restriction, intermittent fasting, and ketogenic diets can increase BDNF expression through metabolic stress pathways[24].
Transplanted cells engineered to secrete BDNF provide another delivery approach:
| Trial | Indication | Intervention | Outcome |
|---|---|---|---|
| Phase I/II (1990s) | ALS | rhBDNF | No significant benefit[27] |
| Phase II | Diabetic neuropathy | rhBDNF | Modest efficacy, injection site pain[28] |
| CERE-120 | Parkinson's disease | AAV-Neurturin | Primary endpoints not met[29] |
Gene therapy approaches using AAV vectors to deliver BDNF or related neurotrophic factors to specific brain regions remain in preclinical development. Recent advances in AAV delivery vectors have renewed interest in this approach[30].
The core obstacle is delivery. BDNF has limited blood-brain barrier penetration and short systemic exposure, which is why many programs move toward AAV gene therapy for neurodegeneration, intraparenchymal delivery, or indirect pathway activation rather than standard peripheral dosing[2:1][3:1].
BDNF is a large molecule (13.5 kDa) that does not readily cross the intact blood-brain barrier. Strategies to overcome this include:
Even when BDNF enters the CNS, diffusion is limited. Targeted delivery to affected brain regions is often necessary, requiring invasive neurosurgical procedures[34].
Systemic or excessive BDNF can cause:
In APP/PS1 transgenic mice, AAV-mediated BDNF delivery to the hippocampus reduced amyloid plaque formation, improved synaptic density, and restored cognitive function[38]. Similar results have been observed in other AD mouse models[39].
BDNF gene therapy in 6-OHDA lesioned rats and MPTP-treated primates protected dopaminergic neurons and improved motor function[40]. Clinical trials have been limited by delivery challenges[41].
BDNF delivery to the striatum in Huntington's disease models reduced GABAergic neuron loss and improved behavioral outcomes[42]. The connection between cortical BDNF production and striatal function is particularly relevant[43].
Emerging approaches include:
BDNF therapy represents a compelling approach to neurodegenerative disease based on solid biological rationale. However, delivery challenges have limited clinical translation. Advances in gene therapy, viral vectors, and alternative delivery methods continue to drive this field forward.
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery. 2011;10(3):209-219. ↩︎ ↩︎
Marvanová M, Lakso M, Pirhonen J, et al. The neuroprotective agent memantine induces brain-derived neurotrophic factor and regulates TrkB, p75NTR and alpha-synuclein levels. Brain Research. 2006;1073-1074:48-59. ↩︎ ↩︎
Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Medicine. 2009;15(3):331-337. ↩︎ ↩︎
Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annual Review of Neuroscience. 2001;24:677-736. ↩︎
Chao MV, Hempstead BL. p75 and Trk: a two-receptor system. Cell. 1995;83(1):5-8. ↩︎
Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Current Opinion in Neurobiology. 2000;10(3):381-391. ↩︎
Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. Journal of Neurochemistry. 2001;76(1):1-10. ↩︎
Minichiello L. TrkB signalling pathways in LTP and learning. Trends in Neurosciences. 2009;32(12):551-561. ↩︎
Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nature Reviews Neuroscience. 2005;6(8):603-614. ↩︎
Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the prefrontal cortex of brains from patients with Alzheimer's disease. Journal of Neurochemistry. 2005;93(6):1412-1421. ↩︎
Mogi M, Togari A, Kondo T, et al. Brain-derived neurotrophic factor concentration in the cerebrospinal fluid of patients with Parkinson's disease. Neuroscience Letters. 1999;270(1):45-47. ↩︎
Baquet ZC, Gorski JA, Jones KR. Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. Journal of Neuroscience. 2004;24(17):4250-4258. ↩︎
Castrén E, Rantamäki T. The role of BDNF and its receptors in depression and antidepressant drug action. Neuropsychopharmacology. 2010;35(1):1-12. ↩︎
Ochs G, Penn RD, York M, et al. A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. 2000;1(3):201-206. ↩︎
Long DK, Burnett MG, Sherriff RL, Thomas CA, Zuccoli G. A phase I study of intraventricularly administered recombinant-methionyl human BDNF (r-methionyl human BDNF) in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2006;7(2):95-100. ↩︎
Nagahara AH, Tuszynski MH. Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nature Reviews Drug Discovery. 2011;10(3):209-219. ↩︎
Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Medicine. 2009;15(3):331-337. ↩︎
Marks WJ Jr, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurology. 2010;9(12):1164-1172. ↩︎
Cotman CW, Berchtold NC, Christie LA. Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends in Neurosciences. 2007;30(9):464-472. ↩︎
Kramer AF, Erickson KI. Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function. Trends in Cognitive Sciences. 2007;11(8):342-348. ↩︎
Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines prevent mitochondrial necrosis. Annals of the New York Academy of Sciences. 2002;962:272-290. ↩︎
Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biological Psychiatry. 2006;59(12):1116-1127. ↩︎
Lauterborn JC, Lynch G, Vanderklish P, et al. Positive AMPA receptor modulation rapidly increases BDNF mRNA but fails to prevent the decline in protein induced by chronic glutamate receptor blockade. Learning & Memory. 2000;7(1):24-31. ↩︎
Mattson MP. Energy intake, meal frequency, and health: a neurobiological perspective. Trends in Neurosciences. 2005;28(5):250-260. ↩︎
Sadan O, Shemesh N, Barzilay R, et al. Adenoviral gene therapy in a rat model of Alzheimer's disease. Gene Therapy. 2012;19(9):891-901. ↩︎
Emerich DF, Winn SR, Hantraye PM, et al. Protection of cholinergic nuclei in the non-human primate by encapsulated cells releasing neurotrophic factors. Experimental Neurology. 1997;143(2):282-289. ↩︎
The BDNF Study Group. A controlled trial of recombinant methionyl human BDNF in ALS. Neurology. 1999;52(7):1427-1433. ↩︎
Apfel SC, Schwartz S, Adornato BT, et al. Efficacy and safety of recombinant human BDNF in diabetic neuropathy. Neurology. 2000;54(5):1152-1155. ↩︎
Bartus RT, Johnson EM Jr. Clinical tests of neurotrophic factors for treating Parkinson's disease. Movement Disorders. 2017;32(1):36-49. ↩︎
Deverman BE, Ravina BM, Bankiewicz KS, et al. Gene therapy for neurological disorders: progress and prospects. Nature Reviews Drug Discovery. 2018;17(10):767-773. ↩︎
Dhuria SV, Hanson LR, Frey WH. Intranasal drug delivery: a promising therapeutic strategy for neurological disorders. Drug Discovery Today. 2010;15(7-8):290-300. ↩︎
Aryal M, Fischer K, Reilly C, et al. Regulated BBB disruption using focused ultrasound. Journal of Controlled Release. 2017;266:238-248. ↩︎
Bakhshetyan K, Siratskyy O, Glover J, et al. Engineering BDNF variants with improved brain penetration. Biomaterials. 2020;230:119280. ↩︎
Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nature Medicine. 2005;11(5):551-555. ↩︎
Tsao J, Jenden DG, Shankar SK, et al. BDNF and weight loss in humans. Brain Research. 2000;876(1-2):200-203. ↩︎
Scharfman HE, Mercurio TC, Goodman JH, et al. Brain-derived neurotrophic factor and epilepsy. Journal of Neurology. 2002;249(7):845-852. ↩︎
Isaacson LG, Onifer SM. Exogenous BDNF increases neuron size in the adult rat spinal cord. Journal of Comparative Neurology. 1997;378(3):455-465. ↩︎
Nagahara AH, Merrill DA, Coppola G, et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nature Medicine. 2009;15(3):331-337. ↩︎
Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al. Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proceedings of the National Academy of Sciences. 2009;106(32):13594-13599. ↩︎
Levivier M, Przedborski S. Neural transplants and neurotrophic factors. Neurobiology of Disease. 1998;5(5):299-314. ↩︎
Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science. 2000;290(5492):767-773. ↩︎
Bemelmans AP, Horellou P, Pradier L, et al. Brain-derived neurotrophic factor-expressing adenoviral vectors prevent cell death in a mouse model of Huntington's disease. Human Gene Therapy. 1999;10(18):2989-3001. ↩︎
Strand AD, Baquet ZC, Aragaki AK, et al. Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor deficiency plays a key role in neuronal dysfunction. Molecular and Cellular Neurosciences. 2007;35(1):199-215. ↩︎
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204-1222. ↩︎
Kells AP, Hadaczek P, Yin D, et al. Efficient gene therapy in mouse and primate brain using AAV vectors. Molecular Therapy. 2011;19(6):1078-1088. ↩︎
Chtarto A, Humbert-Claude M, Bockstael O, et al. Doxycycline-controlled gene expression systems for gene therapy. Gene Therapy. 2007;14(4):309-317. ↩︎
Deverman BE, Ravina BM, Bankiewicz KS, et al. Gene therapy for neurological disorders: progress and prospects. Nature Reviews Drug Discovery. 2018;17(10):767-773. ↩︎